This OpportunitySCAN is a comprehensive opportunity assessment investigating emerging vaccine approaches focused on infections caused by the hospital "superbug", Staphylococcus aureus (MRSA).
The study draws upon qualitative research with global experts in the US and EU regarding current disease dynamics and the scientific viability of immunologic based strategies. Within the document, the reader can access target product profiles (TPPs) for the vaccine, along with definition of target populations and early indications on vaccine pricing benchmarks. The study also discusses the potential impact of CA-MRSA upon vaccine development. OpportunitySCAN Staphylococcus aureus compliments other available research products also published by VacZine Analytics focused on nosocomial infections.
